Affiliation:
1. The University of North Carolina at Chapel Hill, Chapel Hill, NC
Abstract
The COVID-19 pandemic has highlighted the critical role that animal models play in elucidating the pathogenesis of emerging diseases and rapidly analyzing potential medical countermeasures. Relevant pathologic outcomes are paramount in evaluating preclinical models and therapeutic outcomes and require careful advance planning. While there are numerous guidelines for attaining high-quality pathology specimens in routine animal studies, preclinical studies using coronaviruses are often conducted under biosafety level-3 (BSL3) conditions, which pose unique challenges and technical limitations. In such settings, rather than foregoing pathologic outcomes because of the inherent constraints of high-containment laboratory protocols, modifications can be made to conventional best practices of specimen collection. Particularly for those unfamiliar with working in a high-containment laboratory, the authors describe the logistics of conducting such work, focusing on animal experiments in BSL3 conditions. To promote scientific rigor and reproducibility and maximize the value of animal use, the authors provide specific points to be considered before, during, and following a high-containment animal study. The authors provide procedural modifications for attaining good quality pathologic assessment of the mouse lung, central nervous system, and blood specimens under high-containment conditions while being conscientious to maximize animal use for other concurrent assays.
Funder
national institutes of health
NCI Center Core Support
Reference38 articles.
1. AAAS Center for Science, Technology and Security Policy, AAAS Program on Scientific Freedom, Responsibility and Law. Biological safety training programs as a component of reliability: workshop report. 2009. Accessed July 1, 2021. https://www.aaas.org/sites/default/files/s3fs-public/AAAS-Biosafety-report.pdf.
2. Virus inactivation by nucleic acid extraction reagents
3. A comparison of fixation methods on lung morphology in a murine model of emphysema
4. Burr R. Select Agent Program and Biosafety Improvement Act of 2009. Sect. 111th Congress February 26, 2009. Accessed July 1, 2021. https://www.congress.gov/bill/111th-congress/senate-bill/485/text?r=126&s=1.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献